
Eva Morava
Director, Genetics Residency and Fellowship Training Programs · Icahn School of Medicine at Mount Sinai
Credentials: · · · · · ·
History
- Present
Internal Medicine/Medical Genetics Residency Program · Icahn School of Medicine at Mount Sinai
- 1990–1992
Medical Genetics and Genomics
- 1986–1990
Doctor of Medicine
Research
TMEM70 deficiency: long-term outcome of 48 patients
Journal of Inherited Metabolic Disease · 2015 · 53 citations
Impact of integrated translational research on clinical exome sequencing
Genetics in Medicine · 2021 · 32 citations
Mitochondrion · 2011 · 17 citations
- AS
1 paper

1 paper

1 paper

1 paper
- CK
1 paper

1 paper

1 paper
- DB
1 paper
Grants
- 2025–2030
Investigation of Neural Pathogenic Mechanisms Associated with Congenital Disorders of Glycosylation
National Institute of Neurological Disorders and Stroke · P01
Contact PI · $2.5M · Icahn School of Medicine at Mount Sinai
- 2008–2030
T32 Training Grant in Medical Genetics.
National Institute of General Medical Sciences · T32
Contact PI · $579.3K · Icahn School of Medicine at Mount Sinai
- 2023–2027
Pathobiological Mechanisms of Cardiac Disease in PGM1-CDG
National Heart, Lung, and Blood Institute · R01
PI · $1.9M · Utah State Higher Education System--University of Utah
- 2019–2025
Frontiers in Congenital Disorders of Glycosylation
National Institute of Neurological Disorders and Stroke · U54
Contact PI · $8.2M · Icahn School of Medicine at Mount Sinai
Clinical trials
- 2027–2028
AVTX-801 D-galactose Supplementation in SLC35A2-CDG
Principal investigator · Not yet recruiting · Phase 2
Eva Morava-Kozicz
- 2026–2028
Evaluating the Efficacy and Safety of D-galactose in PGM1-CDG (AVTX-801)
Principal investigator · Not yet recruiting · Phase 2
Eva Morava-Kozicz
- 2022–2025
Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG
Principal investigator · Terminated · Phase 3
Maggie's Pearl, LLC
- 2021–2024
Acetazolamide Efficacy in Ataxia in PMM2-CDG
Principal investigator · Terminated · Phase 2, Phase 3
Mayo Clinic
